Job Description
This is for a 6-month full-time co-op from July to December 2021
Summary
Our group, global biometrics non-clinical and clinical biomarker biostatistics, consists of biostatisticians, machine learning researchers, and statistical geneticists. We develop innovative statistical pipelines for upcoming technologies such scRNAseq, snRNAseq, and spatial transcriptomics to aid in the discovery of new drug targets. Our team members also create statistical solutions for problems in research, biomarker development, and PO&T in order to increase Biogens probability of success.
Position Description
Spatial transcriptomics is a new technology to perform mRNA expression profiling of a tissue while also providing spatial information of the gene expression activity. This spatial gene expression information can yield new insights into disease pathology, gene expression in distinct biological compartments, expression profiles in rare cell populations, and expression profiling along contours. Specifically, Biogen is interested in spatial transcriptomics to understand lesion development and expansion in multiple sclerosis (MS).
Analytics and Data Sciences in conjunction with Translational Biology will co-lead the internship project. The intern will focus on improving Biogens current analysis pipeline for spatial gene expression profiling by reading associated literature, developing exploratory simulations to compare analysis approaches, and finally implementing the analysis pipeline as an R package. If time permits, the intern will work on integration of single nuclei RNAseq (snRNAseq) and spatial transcriptomics data for mouse models as well as human brain MS lesions.
Specifically, the intern will:
Investigate literature and available R/python packages to discover the latest algorithms for spatial gene expression analysis
Perform simulation and benchmarking studies to determine performance characteristics of different spatial analysis approaches
Refine/improve current statistical analysis pipelines at Biogen for spatial gene expression analysis. This may involve theoretical exploration of different spatial correlation structures, model forms, missing data imputation strategies, QC filtering approaches, or visualization algorithms
Develop an R package which implements a standardized analysis pipeline for spatial gene expression analysis and outputs results in a specific data format
Qualifications
Qualifications
To participate in the Biogen Internship Program, students must meet the following eligibility criteria:
Legal authorization to work in the U.S.
Grade point average of 3.2 or higher preferred
At least 18 years of age prior to the scheduled start date
Be currently enrolled in an accredited college or university
Additional Qualifications:
Experience with R and/or python programming
Experience with biostatistics and biostatistical simulation
Some familiarity with gene expression technologies (microarray, RNAseq, scRNAseq, snRNAseq, etc)
Education
MS or PhD in biostatistics or related area
Location
Cambridge, MA
Additional Information
All your information will be kept confidential according to EEO guidelines.
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.